Exercise Testing in Mitral Regurgitation. by DULGHERU, Raluca Elena et al.
P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X X
Ava i l ab l e on l i ne a t www.sc i enced i rec t . com
ScienceDirect
www.on l i nepcd .comExercise Testing in Mitral RegurgitationRaluca Dulgherua, Stella Marchettaa, Tadafumi Sugimotoa, Yun Yun Gob,
Alexandra Girbeaa, Cécile Ouryc, Patrizio Lancellottia, c, d,⁎
aUniversity of Liège Hospital, Department of Cardiology, Heart Valve Clinic, Liège, Belgium
bNational Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
cGIGA Cardiovascular Sciences, University Hospital Sart Tilman, Liège, Belgium
dGruppo Villa Maria Care and Research, Anthea Hospital, Bari, ItalyA R T I C L E I N F OStatement of conflict of interest: see page
⁎ Address reprint requests to Patrizio Lance
Cardiology, University Hospital, Université d
E-mail address: plancellotti@chu.ulg.ac.be
https://doi.org/10.1016/j.pcad.2017.10.004
0033-0620/© 2017 Elsevier Inc. All rights rese
Please cite this article as: Dulgheru R, et
10.1016/j.pcad.2017.10.004A B S T R A C TKeywords: Mitral regurgitation (MR) is the second most common valvular heart disease referred for
corrective surgery. Diagnostic and management dilemmas are not uncommon when
dealing with MR patients. Exercise testing plays an important role in sorting out some of
these clinical challenges. In primary asymptomatic MR, exercise testing allows symptom
assessment, confident link of symptoms to valve disease severity, safe deferral of surgery
for the next 1-year in patients with preserved exercise capacity, insights into the
mechanism of exercise-induced dyspnea and helps in individual risk stratification.
Moreover, exercise testing in the form of exercise stress echocardiography is also useful
in the evaluation of patients with secondary ischemic MR for risk stratification as well as for
the detection of patients with moderate ischemic MR in whom mitral valve repair at the
time of surgical revascularization may add benefit.
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Abbreviations and Acronyms
ACC = American College
Cardiology
AF = Atrial fibrillation
BNP = Brain natriuretic peptide
BP = Blood pressure
CPET = Cardiopulmonary exer-
cise testing
CRT = Cardiac resynchronization
therapy
EROA = Effective regurgitant ori-
fice area
ESC = European Society of
Cardiology
ESE = Exercise stress
echocardiography
GLS = Global longitudinal strain
HF = Heart failure
HRR = heart rate recovery
LA = Left atrial
LV = Left ventricular
LVEF = Left ventricular ejection
fraction
MR = Mitral regurgitation
MV = Mitral valve
PAP = Pulmonary artery pressure
PH = Pulmonary hypertension
RV = Right ventricular
RVSP = Right ventricular systolic
pressure
SBP = Systolic blood pressure
SMR = Secondary mitral
regurgitation
SPAP = Systolic pulmonary artery
pressure
VHD = Valvular heart disease
VO2 = Oxygen consumption
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gurgitation (MR) is the
second most common
valvular heart disease
(VHD) referred for cor-
rective surgery.1 It is
also the valvulopathy






of MR may be encoun-
tered. In primary MR,
it is the MV apparatus
(i.e. leaflets, annulus,
chordae or combina-
tion) that carries the
disease. The left ven-




quences of the chron-
ic volume overload
imposed by the MR.
To the opposite, sec-
ondary MR is the re-
sult of a diseased LV,
while MV apparatus is
intact. It is the MV





turn, secondary MR is
also a contributor to
LV dilatation and dys-
function. The cardinal
symptom of MR is
exercise-dyspnea or,in the advanced form, signs and symptoms of overt heart
failure. However, in developed countries, due to the high
accessibility to the medical system, the diagnosis is usually
made earlier in the disease's course, when patients are still
asymptomatic. For secondary MR and patients with asymp-
tomatic primary MR, the full clinical impact of the disease is
underestimated whenever work-up ends with a simple
transthoracic echocardiography (TTE). To this regard and for, et al. Exercise Testing in Mtheir risk stratification capabilities exercise testing is advo-
cated by the current guidelines on themanagement of VHD.2,3
This review will address the role of exercise testing in both
primary and secondary MR.Primary MR
The complex tale of exercise testing – why do we even bother?
When present and if uncorrected, MR impacts patient's
survival.4 Surgery and, more recently, transcatheter therapies
(for high surgical risk patients) are the only available
treatments that improve patient's outcome.5,6 Based on the
current evidence, surgery is recommended (Class I) in
patients with severe MR when they are symptomatic (but
have a LV ejection fraction (LVEF) >30%) or have overt LV
systolic dysfunction (i.e. LVEF ≤60% but >30% or an
end-systolic LV diameter ≥45 mm (for European Society of
Cardiology ESC)/≥40 mm [for American College of Cardiology
(ACC)/American Heart Association (AHA)]).2,3 Although, these
indications for surgery appear crystal clear, in clinical practice
things may get complicated.
Linking symptoms to MR
Since surgery is indicated once the patient becomes symp-
tomatic, identifying those who are truly asymptomatic is
fundamental. Exercise stress testing is an objective way of
confirming the absence of symptoms and to define one's true
functional capacity, compared against age-gender predicted
standards. Not infrequently, patients adapt their daily activ-
ities in order to avoid symptoms. However, exercise-induced
dyspnea as presenting symptom may be subjective and
difficult to objectively link to valve disease itself, since
dyspnea may have multiple causes (deconditioning, obesity,
pulmonary disease, etc.). To this regard, exercise stress
echocardiography (ESE) may be used as a rewarding modality
to assess the true hemodynamic consequences of MR and to
match symptoms with the severity of cardiac involvement
secondary to MR.
Exercise testing in truly asymptomatic patients
The management of asymptomatic patients with severe
primary MR and no LV enlargement or dysfunction remains
a source of debate. The recent ACC/AHA guidelines, however,
advocate MV repair (Class IIa) in these patients when there is
>95% likelihood of a successful and durable repair without
residual MR, and a <1% expected mortality rate in a center of
excellence.3,7 Similar reasonable indication exists in the ESC
guidelines but in patients with flail MV or significantly dilated
LA(IIa).2 Other reasonable triggers for surgery (class IIa)itral Regurgitation, Prog Cardiovasc Dis (2017), https://doi.org/
Table 1 – Summary of different modalities and protocols used in exercise testing.
Modality Protocol Associated Modality Timing of Imaging
Treadmill Bruce Echocardiography Post-exercise
Upstanding bicycle Modified Bruce Pulmonary gas exchange analysis (CPET) Post-exercise
Semi-supine bicycle Naughton Echocardiography and pulmonary gas exchange analysis (CPET) During exercise
3P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X Xinclude increased systolic pulmonary artery pressure (SPAP
>50 mm Hg), or development of atrial fibrillation (AF).8–10 So,
since prophylactic surgery is not unanimously contemplated
in all asymptomatic patients with severe MR, patient's
management is often dictated by individual risk stratification.
ESE provides a series of prognostic features that could help
clinical decision-making; early guidance to mitral valve
intervention, closer follow-up, or safe watchful waiting.11–19
Exercise testing modalities and protocols
ESE can be performed using either a treadmill or bicycle
ergometer, with a symptom-limited protocol in which the
workload is gradually increased in stages (Table 1). The most
common treadmill protocol used is the Bruce (or modified)
protocol, in which the expected exercise level for a given age
and sex can be expressed as functional aerobic capacity. Image
acquisition takes place rapidly after exercise cessation and
focuses first on regional wall motion (hence LV regional and
global systolic function) and right ventricular (RV) systolic
pressure (RVSP).17,18 When compared with cycle ergometer,
treadmill exercise has the advantage of reaching higher
workloads and heart rates. Semi-supine bicycle exercise is
usually the preferred approach because it allows the assess-
ment ofmultiple stress parameters during each step of exercise
testing (Figs. 1–3). At peak exercise, focus is set on the LV
systolic function, MR severity, E/e′ (an estimate of LV filling
pressure), RVSP and RV function (Fig. 1).20 The patient pedals at
a constant cadence against an increasing workload, which
starts at 25 W (50 W for younger patients)with increments of 25
watts every 2 or 3 min. Adequate bicycle stress testing requires
the patient's cooperation and coordination to perform the
pedaling action and this may be a disadvantage.20 Appearance
of symptoms should be assessed regularly, and blood pressure
(BP), heart rate and a 12-lead ECG should be monitored
continuously during the examination. Criteria for interruption
are the target heart rate achievement, or onset of typical chest
pain, ≥2 mm horizontal or downsloping ST segment depres-
sion, limiting breathlessness, dizziness, hypotension (systolic
BP/SBP drop below baseline), complex ventricular arrhythmia
and muscular exhaustion. Of note, cardiopulmonary exercise
testing (CPET) with measurement of gas exchange, which has
the advantage of providing quantitative evaluation of maximal
exercise capacity, can also be useful in patients with primary
MR.21 CPET can be combined with echocardiographic
evaluation.
Clinical value of standard exercise testing
BP response to exercise is clinically meaningful and easy to
access. A drop in SBP during exercise may reflect thePlease cite this article as: Dulgheru R, et al. Exercise Testing in M
10.1016/j.pcad.2017.10.004time-point during exercise testing at which severe MR is
compromising the ability of the LV to increase cardiac output.
In the light of recent research, treadmill exercise may be
useful to identify a subset of asymptomatic patients with
severe primary MR in whom conservative treatment may be
initially deferred.17,18 In fact, in case of preserved exercise
capacity, delaying MV surgery by ≥1 year did not adversely
affect outcomes.18 Conversely, patients achieving <85% of
predictedmetabolic equivalents whichmay be observed in up
to 30%, or those with an abnormal heart rate recovery (HRR;
<18 beat drop in heart rate over 1 min in recovery; probably a
marker of impaired vagal activity) have an increased risk of
events (all-cause mortality, myocardial infarction, stroke, AF
or progression to congestive heart failure/HF), which might be
used as incentive findings for referring patients to surgery. In
daily practice, the clinical usefulness of exercise capacity
assessment may be hampered by several confounding factors
since it is the result of the integrated function of the
cardiovascular, respiratory and musculoskeletal systems.
Therefore, once a patient with altered exercise capacity is
detected, the next step is to corroborate it with MR
consequences.
CPET as a complementary tool
MR may negatively affect exercise capacity through a reduc-
tion of cardiac output and its resulting retrograde pressure
elevation in the pulmonary venous systems. The interest of
CPET in patients with severe asymptomatic primary MR
results from its ability to assess their pulmonary hemody-
namic status (ventilatory efficiency), and their aerobic capac-
ity (cardiac output adaptation to exercise). Peak oxygen
consumption (peak VO2) may be considered as a marker of
the degree to which primary MR may compromise cardiac
output and therefore aerobic capacity. Recent studies have
shown that age-gender predicted VO2 varies widely in these
patients with severe asymptomatic primary MR.19 Up to 20%
of them actually have reduced functional capacity (≤84%
age-gender expected peak VO2), which related to E/e′, lower
stroke volume, the presence of AF, but not to the severity of
MR. In this study, reduced functional capacity (i.e. peak VO2
≤84% age-gender predicted peak VO2) was an independent
marker of higher mid-term risk of clinical events (death, HF or
new severe symptoms, new atrial arrhythmia) or surgery.19
Interestingly, in patients with asymptomatic moderate to
severe primary MR, exercise pulmonary hypertension (PH), a
predictor of symptom onset, is an independent echocardio-
graphic determinant of peak VO2 and VE/VCOE slope, an
estimate of ventilator efficiency.21,22 In practice, although of
interest, especially for longitudinal monitoring, CPET is rarely
used in patients with MR.itral Regurgitation, Prog Cardiovasc Dis (2017), https://doi.org/
Fig. 1 – Flow-chart on how to perform an exercise stress
echocardiography on a semi-supine tilting table.
ESE-exercise stress echocardiography; TTG-transtricuspid
systolic pressure gradient; E/e′-ratio between early diastolic
velocity at the mitral leaflet's tips to early diastolic velocity
by TDI at the level of the medial mitral annulus; MR-mitral
regurgitation; LV-left ventricle; 4Ch-apical four chambers
view; 2Ch-apical two chambers view; 3Ch-apical three
chambers view.
4 P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X XThe added value of ESE
In patients with primaryMR, ESE, as any other exercise test, may
be used to provoke symptoms. SBP drop and abnormal HRRmay
also be detected. However, in our experience, ESE has a
remarkable added value in the understanding of hemodynamics,
linking symptoms to changinghemodynamics, risk stratification,
and ultimately management of patients with primary MR.
Although there is less evidence available, the test seems also
reasonable in symptomatic patients with at least moderate
MR.12,15 The increase in MR severity (≥1 grade),12,23 exercisePlease cite this article as: Dulgheru R, et al. Exercise Testing in M
10.1016/j.pcad.2017.10.004induced PH (exercise systolic pulmonary artery pressure or SPAP
≥60 mm Hg),15,16,24 the absence of LV contractile reserve (<5%
increase in EF or <−2% increment in global longitudinal strain
(GLS)),11,25 and failure of the right ventricle to cope with the
excessively highpulmonary artery pressure (PAP) during exercise
(quantified by tricuspid annular plane systolic excursion
<18 mm)24 are all parameters of poor prognosis in asymptomatic
patients with severe primary MR. Their systematic assessment
during ESE is recommended, whenever possible.
Exercise-induced changes in MR severity
Primary MR may be a highly dynamic entity.12,26 In chronic
asymptomatic primary MR, marked exercise-induced augmen-
tation inMR severity (Effective Regurgitant Orifice Area or EROA
≥10 mm2 and regurgitant volume ≥15 ml) is present in 1/3 of
patients and unrelated to restingMR severity.12 Themagnitude
of this augmentation is correlated with exercise-induced
variation in SPAP and reduced symptom-free survival.12,27
Exercise-induced PH
In severe primaryMR, progressive increase in LV filling pressures
and LA pressure leads to a backward passive rise in pressure in
the pulmonary veins and to post-capillary PH. When present at
rest, PH is amarker of poor outcome and surgery is advised (class
IIa indication in both guidelines).2,3 However, in truly asymp-
tomatic patients, PH at rest is a seldom finding. Conversely,
exercise PH is more common (up to 46% in one study) in this
group of asymptomatic patients,27 even when no PH is noted at
rest.16,27 Patients who developed exercise PH and stop exercise
for dyspnea have higher increase in regurgitant volumes and
larger increase in EROA with exercise.27 Hence, at least in part,
the increase inMR severity with exercisemay be reflected by the
increase in PAP (Fig. 2). Also, exercise PH predicts symptoms
onset.27 A recent study showed that at 3-year follow-up, only 20%
of the patients with exercise PH at baseline remained free of
symptoms.24,27 Exercise PH is also associatedwith ahigher rate of
cardiac death, HF hospitalization, stroke or AF after MV
surgery.13,27 PH at exercise (>60 mm Hg, class IIb) can also be
considered as a trigger for MV repair in low risk patients.2
In practice, abnormal values of SPAP during exercise should
be considered carefully due to confounding factors (i.e., age,
cardiac output, andexerciseprotocol). The timingandmagnitude
of exercise-induced changes in SPAP within the exercise test
protocol rather than SPAP at peak exercise, seems to contain
most of the information regarding pulmonary vascular function
adaptation.28 Slowlyprogressing increase inSPAPduring exercise
with development of exercise PH at end-stages should not
necessarily be labeled as abnormal, especially in elderly patients
or in those reaching age-gender predictedworkload. Thismay be
perceived as normal adaptation to exercise.29 Conversely, early
and steep increases in SPAP (>60 mm Hg) at the first stages of
exercise followed by a plateau often imply an advanced disease
process with exercise symptoms and RV dysfunction.30
LV systolic function reserve to exercise
In MR, the LV dimensions and LVEF reflect the heart's ability to
adapt to increasedvolume load.31However, LVcontractile function
may already be impaired even in the setting of a preserved LVEF at
rest. Lack of contractile reserve (<4% increase in LVEF or aitral Regurgitation, Prog Cardiovasc Dis (2017), https://doi.org/
Fig. 2 – Asymptomatic female patient with moderate primary MR at rest due to posterior leaflet prolapse. There is no severe LV
dilatation (end-diastolic diameter of 48 mm, end-systolic diameter of 33 mm). LV systolic function is normal, with preserved
LV longitudinal function at rest (GLS = −23.4%). There is no pulmonary hypertension at rest (TTG = 24 mm Hg). During exercise
(lower panel) MR becomes severe (ΔEROA = 10 mm2, ΔRV = 8 ml), there is no increase in GLS and the patient develops severe
pulmonary hypertension at the heart rate of 120 bpm and at the second stage of exercise protocol (50 W). She stops the
exercise test for dyspnea. MR-mitral regurgitation; LV-left ventricle; EROA-effective regurgitant orifice area; RV-regurgitant
volume; GLS-global longitudinal strain by speckle tracking; TTG-transtricuspid systolic pressure gradient.
5P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X Xpost-exercise end-systolic volume index >25 cm3/m2) is an early
marker of impaired myocyte contractility and predicts
post-operative LV function after MV surgery, as well as symptom
development and progressive deterioration of LV function in
medically treated patients.31 Recent studies have suggested
that 2D strain imaging obtained at rest and during exercise
could be more sensitive at detecting subclinical LV
dysfunction.11,32,33 A GLS below −20% is associated with LV
systolic dysfunction afterMVsurgery,31 and is a predictor of poorer
event-free survival.11,33 Moreover, the absence of contractile
reserve (<−2% increase in global longitudinal strain during
exercise) predicts postoperative LV dysfunction as well as a 2-fold
increase in risk of cardiac events at follow-up (cardiovascular
death, symptoms or development of LV systolic dysfunction,
hospitalization for acute pulmonary edema or HF) in
medically-treated patients with a better sensitivity and specificity
than an inadequate increase in LVEF.11 In practice, GLS using 2D
speckle tracking imaging is the recommended approach; it can be
successfully used during exercise, especially in the low stages
when heart rate is in adequacy with the frame rate.11,33
Biomarkers during exercise testing
Brain natriuretic peptide (BNP) – a biomarker synthesized and
secreted by cardiac myocytes in response to increased
intracavitary pressure and wall stress, is a valuable surrogate
marker of MR consequences on the LV, LA and PAP both at
rest and during exercise.34–36 A recent study has shown that
in asymptomatic patients with moderate or severe primary
MR and normal LV dimensions and function, elevated
exercise BNP was independently associated with a higher
risk of cardiac events at mid-term follow-up.14 The mainPlease cite this article as: Dulgheru R, et al. Exercise Testing in M
10.1016/j.pcad.2017.10.004determinants of exercise BNP levels were resting LV filling
pressures, LA enlargement and exercise induced LV longitu-
dinal dysfunction, i.e. lower exercise GLS. An exercise BNP
level ≥ 64 pg/ml was the best cut-off value to predict cardiac
events.14 Further studies are needed to confirm the added
value of exercise BNP in patients with primary MR.
A summary of all exercise testing derived parameters
associated with poor outcome in asymptomatic patients with
severe primary MR is provided in Table 2. A schematic
representation of exercise testing modalities in the manage-
ment of patients with primary MR is shown in Fig. 3.Secondary MR
Chronic secondary MR (SMR) is frequently encountered in HF
patients with LV systolic dysfunction of ischemic or
non-ischemic etiology.37 It develops due to a combination of
mitral leaflet tethering secondary to LV dilatation/deformation
with papillary displacement/disco-ordination, annular dilata-
tion/dysfunction, insufficient LV-generated closing forces due
to reduction of LV contractility, and global LV/papillary muscle
dyssynchrony; SMR is dynamic and affected by changes in
hemodynamic conditions, which occur during exercise. Hence,
ESE gives the perfect opportunity for the clinician to take a
glimpse into the complexity of secondaryMR in each individual
patient and offers valuable clinical information.
Role of ESE
ESE is a reliable tool to assess the dynamic nature of chronic
secondary MR (Fig. 4). Based on our experience, ESE may be ofitral Regurgitation, Prog Cardiovasc Dis (2017), https://doi.org/
Fig. 3 – Flow-chart on the management of a patient with severe primary MR. MR-mitral regurgitation; METs-metabolic
equivalents; FUP-follow-up; CPET-cardiopulmonary exercise testing; ESE-exercise stress echocardiography; peak VO2-peak
oxygen consumption; VE/VCO2 the slope of the linear relationship between ventilation (VE) and carbon dioxide output (VCO2);
PHT-pulmonary hypertension.
6 P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X Xinterest in the following conditions: 1) in patients with LV
dysfunction who present with exertional dyspnea out of
proportion to the severity of resting LV dysfunction or MR
severity, 2) in patients in whom acute pulmonary edema
occurs without any obvious cause; 3) to unmask patients at
high risk of mortality and HF (increase in MR severity and PH
with exercise); 4) before surgical revascularization in patients
with moderate MR and 5) following surgery, to identify
persistence of PH and explain the absence of functional class
improvement.38–40
The severity of SMR at rest is unrelated to themagnitude of
MR changes during exercise. About 30% of patients may have
a marked increase in MR with exercise accompanied by an
increase in SPAP.41 The degree of exercise-induced changes in
MR severity relates to changes in LV remodelling,42 in valvularPlease cite this article as: Dulgheru R, et al. Exercise Testing in M
10.1016/j.pcad.2017.10.004deformation and41,42 in LV and papillary muscles
synchronicity.43 Rarely, transient myocardial ischemia may
lead to transient SMR. The induction of ischemia during ESE
can be easily detected by new or worsening wall motion
abnormalities secondary to a hemodynamically significant
stenosis of the right or circumflex coronary artery. Myocardial
revascularization alone may solve MR in such cases.
The magnitude of increase in MR and SPAP is more
pronounced in patients with exercise-limiting dyspnea and
in those hospitalized for acute pulmonary edema.38 The
increase in MR degree during exercise (i.e. increase in EROA
≥13 mm2) independently predicts cardiac death and HF
admission in patients with systolic heart failure and at least
mild secondary ischemic MR.39 The best predictive cut-off
value for the increase in SPAP associated with the outcome isitral Regurgitation, Prog Cardiovasc Dis (2017), https://doi.org/
Table 2 – Parameters of poor prognosis in asymptomatic primary MR.
Parameter Type of Exercise Testing Study
Symptom development Any type
<85% age-gender-predicted METs Treadmill exercise testing Naji et al.17,18
Abnormal heart rate recovery (<18 beats drop in heart rate
over 1 min in recovery)
Treadmill exercise testing Naji et al.17,18
≤84% age-gender expected peak VO2 Cardiopulmonary exercise testing Messika-Zeitoun et al.19
Exercise induced increase in EROA ≥10 mm2 or in
regurgitant volume ≥15 ml
Exercise stress echocardiography Magne et al.12
Exercise induced systolic pulmonary artery
pressure ≥60 mm Hg




Exercise TAPSE <18 mm Post-exercise stress echocardiography Kusunose et al.24
<4% increase in LVEF post exercise Post-exercise echocardiography Lee et al.31
<−2% increase in GLS during low level exercise stages Exercise stress echocardiography Magne et al.11
Exercise BNP levels ≥64 pg/ml Any type, blood sample drawn 5 min after
exercise cessation
Magne et al.14
Peak VO2-peak oxygen consumption; EROA-effective regurgitant orifice area as assessed by PISA method; TAPSE-tricuspid annulus plane
systolic excursion; LVEF-left ventricle ejection fraction; LV-left ventricle; GLS-global longitudinal strain as assessed by speckle tracking analysis;
BNP-brain natriuretic peptide.
7P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X X21 mm Hg. Exercise induced PH (i.e. SPAP > 60 mm Hg) is
common in secondary MR patients, up to 40% of patients in
one study (Fig. 4).40 It seems to be related more to exercise MR
severity and LV diastolic function than to NYHA class.
Moreover, exercise PH has proven to be a powerful predictor
of the occurrence of HF decompensation, cardiac-related
death, or combined cardiovascular events in these patients.40
The presence of viable myocardium predicts LV reverse
remodelling and a better outcome after revascularization,
beta-blocker therapy and cardiac resynchronization therapy
CRT.44 LV reverse remodelling and reduced mitral apparatus
deformation after CRT are associated with a reduction in both
resting and exercise-induced MR and an improvement in
cardiopulmonary performance.45 Moreover, SMR decreases
more significantly in patients with viability in the region of
the pacing lead after CRT.46
Considering the adverse prognostic implications of the
increase in MR severity with exercise in patients with
moderate SMR, the ESC guidelines suggested combined MV
repair at the time of surgical coronary revascularization inFig. 4 – High-risk patient with secondary ischemic MR. At rest, u
tethering on the mitral valve leaflets (yellow arrows) and no pulm
severe increase in MR (exercise induces change in EROA of 0.39
This is a high-risk patient for future heart failure episodes or mo
orifice area; RV-regurgitant volume; TTG-transtricuspid systolic
Please cite this article as: Dulgheru R, et al. Exercise Testing in M
10.1016/j.pcad.2017.10.004patients in whom such a response has been demonstrated
with ESE (Class IIa).Conclusions
Exercise testing, in its many forms, is useful for the evaluation
of asymptomatic patients with primary MR. It allows symp-
tom assessment, confident link of symptoms to VHD severity
(ESE, CPET), safe deferral of surgery for the next 1-year if the
patient proves to have a preserved exercise capacity, insights
into the mechanism of exercise induced dyspnea (CPET and
ESE) and helps in risk stratification of truly asymptomatic
patients through the assessment of exercise-induced PH, LV
dysfunction andMR increase in severity. For all these reasons,
exercise testing should be encouraged in asymptomatic
patients with primary MR. Moreover, ESE is useful in the
evaluation of patients with ischemic SMR for risk stratifica-
tion as well as for the detection of those with moderate
ischemic MR in whom MV repair at the time of surgicalpper panel, there is moderate ischemic MR, important
onary hypertension. During exercise (lower panel), there is a
cm2) accompanied by pulmonary hypertension and dyspnea.
rtality. MR-mitral regurgitation; EROA-effective regurgitant
pressure gradient.
itral Regurgitation, Prog Cardiovasc Dis (2017), https://doi.org/
8 P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S X X ( 2 0 1 7 ) X X X – X X Xrevascularization may add benefit. The role of ESE in
non-ischemic forms of secondary MR is not yet established
and should be further explored.Statement of conflict of interest
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